Tear function test results in patients with meibomian gland dysfunction

Objective & Hypothesis:Background: To compare Ocular Surface Disease Index [OSDI, Allergan Inc., (Irvine, Calif)] survey, Schirmer test and tear break-up time (TBUT) results in eyes with meibomian gland dysfunction (MGD) and without.

📊

Key Findings & Data:Methods: Thirty two eyes of 16 patients with MGD (Group A) and 32 eyes of 16 healthy subjects (Group B) were evaluated.

💡

Conclusion & Impact:The mean OSDI survey scoring was 45.5±15 in Group A and 9.4±37 in Group B, and there was a statistically significant difference between two groups (p

🔬Design:Survey & Empirical Study

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Background: To compare Ocular Surface Disease Index [OSDI, Allergan Inc., (Irvine, Calif)] survey, Schirmer test and tear break-up time (TBUT) results in eyes with meibomian gland dysfunction (MGD) and without. Methods: Thirty two eyes of 16 patients with MGD (Group A) and 32 eyes of 16 healthy subjects (Group B) were evaluated. After performing visual acuity and detailed ophthalmic exami- nation, OSDI survey was performed in all patients. Schirmer test without anesthesia and TBUT measurement were applied to all patients. Results: The mean age of Group A was 26.9±4.9 years (10 female, 6 male) and Group B was 27.3±5.1 years (9 female, 7 male). There was no statistical difference in age and sex between the two groups (p=0,65; p=0,78). Monocular best-corrected visual acu- ity with Snellen chart was 10/10 in all patients. The mean OSDI survey scoring was 45.5±15 in Group A and 9.4±37 in Group B, and there was a statistically significant difference between two groups (p

Özet

Amaç: Meibomius bezi disfonksiyonu (MBD) olan hastalarla kontrol grubu hastaların Oküler Yüzey Hasar İndeksi (OSDI, Allergan Inc., [Irvine, Calif ]) anketi, Schirmer testi ve gözyaşı kırılma zamanı (GKZ) sonuçlarını karşılaştırmak. Gereç ve Yöntem: MBD olan 16 hastanın 32 gözü (Grup A) ve kontrol grubu olarak 16 hastanın 32 gözü (Grup B) çalışma- ya alındı. Tüm hastaların görme keskinliği muayenesi ve ay- rıntılı oftalmolojik incelemesi yapıldıktan sonra OSDI anketi ile semptomları sorgulandı. Kuru göz tanısı için anestezisiz Schirmer testi ve GKZ testleri uygulandı. Bulgular: Grup Ada yaş ortalaması 26.9±4.9 (10 kadın, 6 erkek) iken, B grubunda yaş ortalaması 27.3±5.1 yaş (9 ka- dın, 7 erkek) idi. İki grup arasında yaş ve cinsiyet açısından anlamlı olarak fark yoktu (p=0.65; p=0.78). Tüm hastaların en iyi düzeltilmiş görme keskinliği Snellen eşeli ile 10/10 idi. OSDI skoru ortalaması Grup Ada 45.5±15.1 iken, B grubunda 9.4±3.7 idi ve iki grup arasında ileri derecede anlamlı fark bu- lundu (p

🔖

Cite This Article

KAHYA, A., SAYMAN, I. B. M., ÖZERTÜRK, Y. (2022). Tear function test results in patients with meibomian gland dysfunction. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 25 - Sayı: 1, 23–26. https://ajindex.com/articles/571368

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

The definition and classification of dry eye disease: re- port of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):75-92. 2.The epidemiology of dry eye disease: report of the Epi- demiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):93-107. 3.Arciniega JC, Nadji EJ, Butovich IA. Effects of free fatty ac- ids on meibomian lipid films. Exp Eye Res 2011;93(4):452- 9. 4.Goto E, Monden Y, Takano Y, Mori A, Shimmura S, Shima- zaki J, Tsubota K. Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm com- pression device. Br J Ophthalmol 2002;86(12):1403-7. 5.Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 2011;52(4):1930-7. 6.Finis D, Schrader S, Geerling G. Meibomian gland dys- function. [Article in German] Klin Monbl Augenheilkd 2012;229(5):506-13. [Abstract] 7.Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci 2011;52(4):1994-2005. 8.Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, et al. The international workshop on meibo- mian gland dysfunction: report of the diagnosis sub- committee. Invest Ophthalmol Vis Sci 2011;52(4):2006- 49. 9.Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol 1996;40(5):343-67. 10.Cömez AT, Tufan HA, Kocabıyık O, Gencer B. Effects of lubricating agents with different osmolalities on tear os- molarity and other tear function tests in patients with dry eye. Curr Eye Res 2013;38(11):1095-103. 11. Green-Church KB, Butovich I, Willcox M, Borchman D, Paulsen F, Barabino S, et al. The international workshop on meibomian gland dysfunction: report of the sub- committee on tear film lipids and lipid-protein interac- tions in health and disease. Invest Ophthalmol Vis Sci 2011;52(4):1979-93. 12. Demircan A, Altan C, Azman FE, Alkın Z, Kucuksumer Y, Demirok A. Tear properties in eyes with chronic blepha- ritis. Turk J Ophthalmol 2012;42(5):346-8. 13. Evren O. Approach to blepharitis and meibomian gland dysfunction treatment. Türkiye Klinikleri J Surg Med Sci 2007;3(8):43-6.